Vizsgálati helyszín

Cliniq s.r.o.

Bratislava, 81109, SzlovákiaEU-13 felzárkózó országMég nincs intézményhez kötve

35futó vizsgálat
10lezárt vizsgálat

Az itteni vizsgálatok

Miről szól a helyszín 45 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek: Colitis ulcerosa24 vizsgálat
Crohn-betegség15 vizsgálat
Elhízás3 vizsgálat
Atópiás dermatitisz (ekcéma)2 vizsgálat
Hidradenitis suppurativa2 vizsgálat
Szívelégtelenség2 vizsgálat
2-es típusú cukorbetegség1 vizsgálat
Koszorúér-betegség1 vizsgálat
Krónikus vesebetegség1 vizsgálat
Migrén1 vizsgálat
Peripheral artery disease1 vizsgálat
Stroke (szélütés)1 vizsgálat
és még 1
Fázis: 3. fázis28 vizsgálat
2. fázis15 vizsgálat
2/3. fázis1 vizsgálat
4. fázis1 vizsgálat
Állapot: Toboroz18 vizsgálat
Fut, nem toboroz16 vizsgálat
Lezárult9 vizsgálat
Még nem toboroz1 vizsgálat
Leállították1 vizsgálat
Fő szponzor: Eli Lilly and Company7 vizsgálat
Janssen Research & Development, LLC6 vizsgálat
Abivax S.A.4 vizsgálat
AbbVie3 vizsgálat
Takeda3 vizsgálat
és még 17

Futó vizsgálatok

Toboroz
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07690371· 3. fázis· Nektar Therapeutics· Forrás
Toboroz
A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00· 2. fázis· Eli Lilly & Co.· Forrás
Meghívásos bevonás
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
2025-521590-13-00· 3. fázis· Janssen Cilag International· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
NCT07577843· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
NCT07499232· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· 2. fázis· Eli Lilly and Company· Forrás
Contact: Tibor Hlavaty (principal investigator)
Toboroz
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Toboroz
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· 3. fázis· Eli Lilly and Company· Forrás
Contact: Tibor Hlavaty (principal investigator)
Toboroz
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· 3. fázis· Eli Lilly and Company· Forrás
Contact: Tibor Hlavaty (principal investigator)
Toboroz
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
NCT06764615· 2. fázis· Takeda· Forrás
Toboroz
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395· 2. fázis· Spyre Therapeutics, Inc.· Forrás
Toboroz
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· 3. fázis· Boehringer Ingelheim· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· 3. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593· 2. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
NCT06226883· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
NCT06408935· 3. fázis· Janssen-Cilag Ltd.· Forrás
Fut, nem toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
NCT06254950· 2. fázis· Takeda· Forrás
Toboroz
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
ABTECT - Maintenance
NCT05535946· 3. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
NCT05668013· 2. fázis· Teva Branded Pharmaceutical Products R&D LLC· Forrás
Toboroz
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126· 2. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05242484· 2. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis
NCT05177835· 2. fázis· Abivax S.A.· Forrás
Fut, nem toboroz
Effects of ABX464 during long-term treatment in patients with moderate to severe ulcerative colitis
2023-507974-42-00· 2. fázis· Abivax· Forrás
Fut, nem toboroz
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
NCT04232553· 3. fázis· Eli Lilly and Company· Forrás
Fut, nem toboroz
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT04033445· 2/3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
NCT03519945· 3. fázis· Eli Lilly and Company· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

Lezárt vizsgálatok

Lezárult
A study to compare the effect of AVT16 and Entyvio® in subjects with moderate to severe active ulcerative colitis.
2023-507705-34-00· 3. fázis· Alvotech Swiss AG· Forrás
Lezárult
A randomised, double-blind, double-dummy, multicentre, phase III, non inferiority trial of an oral mesalazine formulation in patients with active mild to moderate ulcerative colitis for the induction of remission.
NCT06176560· 3. fázis· Faes Farma S.A.· Forrás
Lezárult
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
NCT06241313· 3. fázis· AbbVie· Forrás
Lezárult
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580· 4. fázis· AbbVie· Forrás
Lezárult
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021· 3. fázis· Eli Lilly and Company· Forrás
Lezárult
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2
NCT05507216· 3. fázis· Abivax S.A.· Forrás
Lezárult
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671· 2. fázis· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Forrás
Fut, nem toboroz
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05528510· 3. fázis· Janssen Research & Development, LLC· Forrás
Leállították
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
NCT04985968· 3. fázis· InDex Pharmaceuticals· Forrás
Lezárult
Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease
2023-510426-33-00· 3. fázis· Celgene International II S.a.r.l.· Forrás

Helyszínadatok: ClinicalTrials.govFrissítve: 2026. nov. 13.

Hibát jelzek